268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

Bibliographic Details
Main Authors: Ignace Vergote, Frédéric Selle, Dominique Berton-Rigaud, Patricia Pautier, Chuan Tian, Anna Kryzhanivska, Antoine Angelergues, Deanna Kornacki, Monika Dudzisz-Sledz, Nawel Bourayou
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items